Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Custirsen + Docetaxel |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Custirsen | Antisense Clusterin|Antisense TRPM-2|OGX-011|CC-8490 | Antisense Therapy 14 | Custirsen (OGX-011) is an antisense oligo targeting clusterin, which leads to apoptosis in tumor cells (PMID: 23130925, PMID: 30732140). | |
| Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT01630733 | Phase III | Docetaxel Custirsen + Docetaxel | A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer | Unknown status | USA | POL | NZL | ITA | ISR | HUN | ESP | DEU | AUS | 6 |